Public Comment and Testimony

Public Comment Before the Presidential Advisory Council on HIV/AIDS

May 16, 2012

Public Comment Before the FDA On In-Home HIV Testing

May 15, 2012

"One of our primary missions is  to reduce the number of new HIV infections...That is why we support approval of the OraQuick In-Home HIV Test."

Comment before the CDC/HRSA Advisory Committee on HIV, Viral Hepatitis and STD Prevention and Treatment

May 10, 2010

PDF is attached below.

Comment Before the FDA on the Use of Truvada as PrEP

May 10, 2012

"Truvada as PrEP introduces an important tool to address the HIV/AIDS epidemic in the United States."

The AIDS Institute's Testimony in Support of FY13 Domestic HIV/AIDS & Hepatitis Programs

April 30, 2012

Written Statement of The AIDS Institute to the Subcommittee on Labor, Health and Human Services, Education and Related Agencies

March 29, 2012

Public Comment by TAI before the President's Advisory Council on HIV/AIDS

February 28, 2012

Comments on the December 16, 2011 Essential Health Benefits Bulletin

January 31, 2012

TAI Public Comment to CDC/HRSA Advisory Committee on HIV, Hepatitis, and STD Prevention/treatment

November 16, 2011

A small ongoing work group should be formed composed of outside partners and HRSA/AIDS Bureau staff to work together to ensure health reform implementation goes as smoothly as possible for people with HIV.

TAI Public Comment to FDA Offers Strong Support for Renewal of the Prescription Drug User Fee Act

October 24, 2011

The AIDS Institute offers its strong support for the proposed recommendations of the fifth renewal of the Prescription Drug User Fee Act (PDUFA), as negotiated between the Federal Drug Administration (FDA) and the pharmaceutical industry.

Syndicate content